ALK and lung cancer: Up to the present, the prevalence of the triple mutation was estimated to be 2–4% among patients with lung cancer according to the frequency of 22% among osimertinib-resistant cases reported in WCLC2015 (ref. 50), and the C797S population would be equal to that of ALK-rearranged lung cancer patients with a similar clinical magnitude.